RxDoctor Payments DataLook up a doctor →

Andrea Randall

Family · Indianapolis, INNPI 1821409467

Payments from drug & device makers

$26,804in general payments, 2019–2025

Across 1,619 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Livanova USA, Inc.$2K
  • MDD US Operations, LLC$2K
  • Novartis$2K
  • Medtronic$1K
  • UCB, Inc.$1K
  • plus $15K from 54 others

What the payments were for

  • Speaking & faculty fees$220%
  • Travel & lodging$1,1464%
  • Food & beverage$25,52795%
  • Education$1090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)332$4,123
Livanova USA, Inc.32$1,783
MDD US Operations, LLC87$1,552
Novartis93$1,509
Medtronic18$1,244
UCB, Inc.88$1,236
Neurocrine Biosciences, Inc.67$1,002
Jazz Pharmaceuticals Inc.38$868
Pfizer71$854
Lilly USA, LLC85$844
Acadia Pharmaceuticals Inc56$767
Eisai Inc.46$754
SK Life Science, Inc.32$738
EMD Serono, Inc.34$689
Argenx US, Inc.34$602
Teva Pharmaceuticals USA, Inc.36$535
Harmony Biosciences LLC32$476
Amgen(2 entities)29$468
Alnylam Pharmaceuticals Inc.20$393
Bristol Myers Squibb24$374
TG Therapeutics, Inc.18$359
Johnson & Johnson26$348
Biogen16$329
Sunovion Pharmaceuticals Inc.24$304
Lundbeck LLC13$296
AstraZeneca13$283
Sanofi14$268
Otsuka America Pharmaceutical, Inc.20$253
Neurelis, Inc.11$230
Biohaven Pharmaceutical Holding Company Ltd.17$223
Biohaven Pharmaceuticals, Inc.15$216
Axsome Therapeutics, Inc.6$204
Genentech USA, Inc.11$201
Supernus Pharmaceuticals, Inc.20$193
Impel Pharmaceuticals Inc.13$178
Catalyst Pharmaceuticals, Inc.7$176
Takeda Pharmaceuticals U.S.A., Inc.7$166
Amneal Pharmaceuticals LLC11$163
Almatica Pharma LLC23$140
Vanda Pharmaceuticals Inc.8$138
Xeris Pharmaceuticals, Inc.7$112
Sumitomo Pharma America, Inc.8$108
Tanabe Pharma America, Inc.5$104
Scilex Pharmaceuticals Inc.5$87
Banner Life Sciences, LLC4$85
Octapharma USA, Inc.4$83
Inspire Medical Systems, Inc.3$66
Acorda Therapeutics, Inc3$59
Grifols USA, LLC3$57
Ipsen Biopharmaceuticals, Inc3$55
Avanir Pharmaceuticals, Inc.3$53
OWP Pharmaceuticals, Inc.3$53
Avadel CNS Pharmaceuticals, LLC2$50
Collegium Pharmaceutical, Inc.3$43
Kyowa Kirin, Inc.2$41
Mallinckrodt Hospital Products Inc.1$39
Cycle Pharmaceuticals Inc2$38
Springworks Therapeutics, Inc.2$37
Azurity Pharmaceuticals, Inc.2$36
Avion Pharmaceuticals2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,804 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$43,507
Medicare patients
122
Services billed
4,967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate34$164,738
EpidiolexCannabidiol (Cbd)19$115,361
PonvoryPonesimod11$104,775
AptiomEslicarbazepine Acetate26$84,083
Nurtec OdtRimegepant Sulfate55$69,609
Emgality PenGalcanezumab-Gnlm72$55,917
Aimovig AutoinjectorErenumab-Aooe44$42,205
UbrelvyUbrogepant30$39,010
RytaryCarbidopa/Levodopa24$31,736
BriviactBrivaracetam17$31,727
GocovriAmantadine Hcl11$17,937
NeuproRotigotine11$16,618
LinzessLinaclotide20$16,171
Lacosamide133$15,330
NayzilamMidazolam14$10,072

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$767$164,73834 claims
Johnson & JohnsonPonvory$348$104,77511 claims
Sunovion Pharmaceuticals Inc.Aptiom$304$84,08326 claims
PfizerNurtec Odt, Dilantin$854$71,39167 claims
UCB, Inc.Briviact, Neupro, Nayzilam$1,236$58,41742 claims
AbbVieUbrelvy, Linzess$4,123$55,18150 claims
Amneal Pharmaceuticals LLCRytary$163$31,73624 claims
MDD US Operations, LLCGocovri$1,552$17,93711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →